secwatch.observer — SEC 8-K summary
======================================

Issuer:     AEON Biopharma, Inc. (AEON)
CIK:        0001837607
Form:       8-K
Filed at:   2026-03-09T23:59:59+00:00
Accession:  0001837607-26-000009
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AEON Biopharma appoints John Bencich as CFO, amends inducement plan by 1M shares
--------------------------------------------------------------------------------

- John Bencich appointed CFO effective March 9, 2026; base salary $450k, bonus target 40%.
- Equity grants: 754,717 RSUs (4-year vest) and 235,849 PSUs tied to NYSE American compliance.
- Jennifer Sy enters CAO employment agreement with $275k base, 30% bonus target, and severance terms.
- Board adds 1,000,000 shares to 2025 Inducement Plan for equity awards without stockholder approval.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1837607/000183760726000009/0001837607-26-000009-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1837607/000183760726000009/aeon-20260306x8k.htm
  HTML page:      https://secwatch.observer/filing/0001837607-26-000009

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer